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Background: Progressive multifocal leukoencephalopathy (PML) is a severe complica-
tion of immunosuppressive therapies, especially of natalizumab in relapsing–remitting 
multiple sclerosis (MS). Metabolic changes within PML lesions have not yet been 
described in natalizumab-associated PML in MS patients.
Objective: To study metabolic profiles in natalizumab-associated PML lesions of MS 
patients by 1H magnetic resonance spectroscopy (1H-MRS) at different stages during 
the PML course. To assess changes associated with the occurrence of the immune 
reconstitution inflammatory syndrome (IRIS).
Methods: 20 patients received 1H-MRS and imaging at 3 T either in the pre-IRIS, IRIS, 
early-post-PML, or late post-PML setting. Five of these patients received individual 
follow-up examinations, including the pre-IRIS or IRIS phase. Clinical worsening was 
described by changes in the Karnofsky Performance Scale (KPS) and the expanded 
disability status scale (EDSS) 1 year before PML and scoring at the time of 1H-MRS.
results: In PML lesions, increased levels of the Lip/Cr ratio, driven by rising of lipid and 
reduction of Creatine, were found before the occurrence of IRIS (p = 0.014) with a maximum 
in the PML–IRIS group (p = 0.004). By contrast, marked rises of Cho/Cr in PML lesions 
were detected exclusively during the IRIS phase (p = 0.003). The Lip/Cr ratio decreased to 
above-normal levels in early-post-PML (p = 0.007, compared to normal appearing white 
matter (NAWM)) and to normal levels in the late-post-PML group. NAA/Cho was reduced 
compared to NAWM in the pre-IRIS, IRIS, and early-post-PML group. In NAA/Cr, the same 
effect was seen in the pre-IRIS and early-post-PML group. These cross-sectional results 
were confirmed by the individual follow-up examinations of four patients. NAA/Cho, Cho/
Cr, and the lipid rise relative to NAWM in PML lesions were significantly correlated with 
the residual clinical worsening (KPS change) in post-PML patients (Spearman correlations 
ρ = 0.481, p = 0.018; ρ = −0.505, p = 0.014; and ρ = −0.488, p = 0.020).
conclusion: 1H-MRS detected clinically significant dynamic changes of metabolic pat-
terns in PML lesions during the course of natalizumab-associated PML in MS patients. 
Lip/Cr and Cho/Cr may provide additional information for detecting the onset of the IRIS 
phase in the course of the PML disease.
Keywords: 1h magnetic resonance spectroscopy, multiple sclerosis, natalizumab, progressive multifocal 
leukoencephalopathy, PMl lesions, immune reconstitution inflammatory syndrome
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Abbreviations: PML, progressive multifocal leukoencephalopathy; JCV, John 
Cunningham Virus; HIV, human immunodeficiency virus; RR-MS, relapsing–
remitting multiple sclerosis; MRI, magnetic resonance imaging; IRIS, immune 
reconstitution inflammatory syndrome; 1H-MRS, 1H magnetic resonance spectros-
copy; NAA, N-acetyl aspartate; Cho, Choline; Cre, Creatine, Lip, Lipid, mI, myo-
Inositol; CSF, cerebrospinal fluid; DNA, desoxyribonucleic acid; EDSS, Expanded 
Disability Status Scale; KPS, Karnofsky Performance Scale; TR, repetition time; TE, 
echo time; TI, inversion time; VOI, volume of interest; NAWM, normal appearing 
white matter.
inTrODUcTiOn
Progressive multifocal leukoencephalopathy (PML) occurs in 
immunocompromised patients as an opportunistic infection 
of the central nervous system caused by the John Cunningham 
Virus (JCV). Patients with a human immunodeficiency virus 
(HIV) infection are mainly affected (1), but it also occurs as a rare 
side effect in natalizumab-treated patients with relapsing–remit-
ting multiple sclerosis (RR-MS) (2). The reactivation of the JCV 
causes a lytic infection of astrocytes, oligodendrocytes, and neu-
rons resulting in severe demyelination (3). Magnetic resonance 
imaging (MRI) techniques are essential for the detection of early 
asymptomatic stages of PML (4) and the immune reconstitution 
inflammatory syndrome (IRIS) (5). Early recognition of PML 
by MRI plays a crucial role for treatment decision-making and 
clinical outcome (4, 6). Even though there are limited data for 
the prognostic value of MRI regarding the clinical outcome of 
PML patients, higher survival rates could be demonstrated in 
more localized manifestations of the disease (unilobar and mul-
tilobar brain involvement) in contrast to widespread PML attack 
within the brain’s white matter (7, 8). Longitudinal observations 
have shown that functional disability in PML survivors usually 
stabilizes at reduced levels after about 6 months and tends to stay 
stable beyond 18  months after PML diagnosis unless new MS 
relapses occur (7, 9).
In HIV-related PML, MRI-based monitoring of PML lesions 
in the course of the disease plays an important role with regard 
to detection of IRIS (10). The occurrence of IRIS in natalizumab-
associated PML in MS is accompanied by the progression of 
clinical disability and imaging findings with contrast enhance-
ment, expanding lesions with edema and mass effects (11, 12). 
The diagnosis of PML–IRIS has a crucial therapeutic relevance 
because treatment with corticosteroids, which is mostly associ-
ated with a better outcome, should not be initialized before any 
signs of immune reconstitution, since this may attenuate the 
specific T-cell response and lead to an unopposed progression of 
PML (13). Because there is still a lack of predictors of the onset 
and severity of PML–IRIS, clinicians may tend to withhold cor-
ticosteroids until a well-demonstrated IRIS response is identified 
(14). The occurrence of contrast enhancement is consistent with 
IRIS, but it is not a unique indicator with regard to the detection 
of PML–IRIS, since it is found in PML–IRIS as well as in early 
inflammation in the acute or asymptomatic disease stages of MS, 
and even simultaneously in PML (10, 15, 16).
Unlike other MR techniques, 1H magnetic resonance spec-
troscopy (1H-MRS) allows to characterize metabolic changes in 
pathological lesions as well as in normal-appearing brain tissue 
(17). However, 1H-MRS results regarding natalizumab-associated 
PML are limited, while more studies relate to HIV-associated PML 
(18, 19). In HIV-associated PML brain lesions, typical MRS find-
ings are as follows: decreased levels of N-acetyl aspartate (NAA), 
increased Choline (Cho), elevated lactate and lipid, and variable 
myo-Inositol (mI) levels. Lesions of patients with HIV-associated 
PML–IRIS showed higher Cho/Creatine and mI/Creatine ratios, 
as well as increased lipid levels and reduced NAA/Creatine ratios 
than patients who did not have IRIS (18). There are a few case 
reports concerning MRS in MS patients with natalizumab-
associated PML. In these studies, decreased NAA and increased 
Cho-levels were observed (20, 21). In a recent work by the authors 
the metabolic profiles in PML lesions of 15 MS patients in the 
post-PML setting have been explored confirming reduced NAA/
Cr and NAA/Cho in early and late post-PML. Persisting JC virus 
findings more than 2 years after PML were associated with higher 
disability. Moreover, higher levels of lipid were detected in the 
early post-PML setting compared to late post-PML (22).
Therefore, the aims of this study were to investigate dynamic 
changes in 1H-MRS patterns in a larger cohort of MS patients 
suffering from natalizumab-associated progressive multifocal 
leukoencephalopathy at different disease stages, including the 
IRIS phase and the time between PML diagnosis and PML–IRIS 
and to examine whether 1H-MRS can provide additional para-
clinical markers for the occurrence of PML–IRIS.
MaTerials anD MeThODs
Patients
We included 20 RR-MS patients (12 females and 8 males) who 
were referred to our clinic with natalizumab-associated PML at 
different stages during the course of PML disease, and classified 
them into different PML status groups: pre-IRIS, IRIS, early 
post-PML, late post-PML. In 5 of these patients we were able to 
perform individual follow-up investigations. Most patients were 
referred to our institution for obtaining a second expert opinion 
at different disease stages. As a result, follow-up investigation 
could only be performed in MS patients treated in our institution 
for suspected PML or in early PML stages before the onset of 
IRIS. In some cases MRI examinations could not be performed 
during PML–IRIS because of the worsening of clinically affection 
requiring intensive care.
We performed MR imaging and 1H-MRS in 5 patients before 
the occurrence of PML–IRIS, one of these patients was scanned 
twice in the pre-IRIS period (pre-IRIS spectra N = 6) and in four 
patients during the occurrence of IRIS (IRIS spectra N = 4). In 
addition, 16 patients were observed after amelioration of the PML. 
Three of them received a follow-up examination (post-PML spec-
tra N = 19). This patient group was further subdivided into two 
subgroups according to the time interval between IRIS and the 
time of MR examination. The early-post-PML group consists of 6 
patients who were examined 12 [6–19] months (median [range]) 
after IRIS, including 2 follow-up scans (early post-PML spectra, 
N = 8). The late post-PML group consisted of 11 patients (includ-
ing 1 patient who was scanned twice) who were scanned after 
38 [23–67] months (median [range]). This subdivision aimed at 
assessing the changes of metabolic patterns in PML lesions by 
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comparing the early-post-PML situation with the late-post-PML 
phase, which is often characterized by a clinical stabilization.
Progressive multifocal leukoencephalopathy–IRIS was defined 
by an inflammatory response resulting in clinical worsening of 
symptoms, which was associated with contrast enhancement 
on MRI in all patients of the IRIS group (23). The details of the 
PML diagnosis and disease course and the functional outcome 
of the study population have been reported recently (24). In 
brief, after the onset of neurological symptoms consistent with 
PML, the diagnosis was verified by JC-virus DNA detection in 
the cerebrospinal fluid (CSF) in 18 patients. In two patients, 
the CSF probes were initially JC-virus-negative, still the clinical 
presentation and MRI findings were indicative of PML (diagnos-
tic accuracy “possible”) and no other differential diagnosis was 
found (25). One of these patients was tested virus positive in a 
follow-up puncture; in the other patient, a follow-up CSF probe 
was not available since the patient rejected the second puncture. 
CSF samples were analyzed for JC-virus DNA at the Department 
of Virology, University of Düsseldorf. The detection limit of the 
method was 10 copies/ml CSF (26). In all included participants 
IRIS associated with gadolinium enhancement in PML lesions 
was observed. After PML diagnosis, all patients received plasma 
exchange or immunoadsorption to remove natalizumab and sup-
portive treatment with mefloquine and mirtazapine (9).
At each given MR examination, the clinical status was extracted 
from the patient files for each patient, including the Expanded 
Disability Status Scale (EDSS) and Karnofsky Performance Scale 
(KPS) (27, 28). The PML-related worsening of EDSS and KPS 
were defined as the EDSS and KPS difference between scoring 
1  year before PML-diagnosis and scoring at the time of MR 
acquisition.
This non-interventional study was carried out in accord-
ance with the recommendations of the ethics committee of the 
Ruhr-University Bochum, Germany (approval no. 4566-13). All 
subjects gave written informed consent in accordance with the 
Declaration of Helsinki.
1h-Mrs and Mr imaging of PMl lesions
1H-MRS and MRI of the brain were performed on a single 3 T 
MRI System (Philips Achieva, Best, The Netherland) using a 
32-channel head matrix coil. To localize the PML lesions and 
position of the volume of interest (VOI) for MRS, isotropic 
3D sequences were performed, consisting of sagittal T1 fast 
field echo (repetition time/echo time TR/TE: 10/4.6  ms, 
inversion time TI: 1,000  ms, echo train length 164, matrix 
240 × 240, 180 slices, resolution 1 mm × 1 mm × 1 mm) with 
and without Gadolinium administration, and sagittal fluid-
attenuated inversion recovery (FLAIR) (TR/TE: 4800/291 ms, 
TI: 1650 ms, echo train length 182, matrix 240 × 240, 170 slices, 
resolution 1  mm ×  1  mm ×  1  mm). For 1H-MRS, a volume 
selective 2D-PRESS chemical shift imaging sequence (TR/TE: 
2,000/45  ms, bandwidth 2,000  Hz, 1,024 spectral points, 128 
measurements) was used to excite a brain region inside the 
skull of 82 mm × 90 mm × 15 mm dimension (left-right × ante-
rior–posterior ×  head–feet dimension). Outer volume signal 
suppression by 10 circular saturation slices (30 mm thickness) 
which were oriented perpendicular to the excited plane was used 
in order to avoid signal distortions by susceptibility artifacts and 
interfering signals of subcutaneous fat.
Spectroscopic imaging was achieved by phase encoding in 
two directions within the excited plane to cover an axial field 
of view of 230  mm  ×  190  mm. The in-plane resolution was 
10 mm × 10 mm × 15 mm. The preparation phase of 1H-MRS 
consisted of automatic procedures for water-suppression, shim-
ming, and tuning of radiofrequency and gradient system, as well 
as an acquisition without water suppression for correction of 
magnetic field distortions.
The excited plane was positioned with the aim of covering PML 
lesions and normal appearing white matter (NAWM). If more 
than one region affected by PML lesions was visible on the FLAIR 
images, the excitation plane was positioned aiming to transect 
the largest lesion. In case of follow-up examinations, care was 
taken to choose identical anatomical locations and voxel sizes. 
Whenever possible, single MS lesions in white matter regions, 
which were apparently not affected by PML, were also covered.
Progressive multifocal leukoencephalopathy lesions were 
identified and differentiated from MS lesions by comparison with 
pre-existing, eventually external MRI scans acquired before the 
onset of PML by experienced raters (RS, CL). Differentiation was 
based on lesion location and morphology (subcortical, adjacent 
to U-fibers, diffuse demarcation to white matter), diffusion 
restriction (if diffusion weighted images were available) and pat-
terns of Gadolinium uptake in the event of IRIS.
Figure 1 demonstrates the course of changes in the metabolic 
patterns in a single patient (no. 1) in the pre-IRIS, IRIS, and 
two post-PML examinations (for details, see Results). The axial 
FLAIR images (middle column) illustrate typical positioning of 
the VOI (green box) covering PML lesions as well as NAWM. 
The evaluated spectra were based on selected single voxels (yellow 
box) corresponding to a volume of 1.5 ml. The PML spectra were 
positioned in the center of the lesions. In follow-up examinations, 
care was taken to choose identical evaluation planes and voxel 
positions. The corresponding contrast-enhanced T1 images (right 
column) show contrast uptake and evolution of T1 hypodensity at 
the location of the PML lesions.
spectral Processing
The vendor’s automatic software SpectroView was used for 1H-
MRS signal post-processing (29, 30). The automatic processing 
included time domain filtering (Gaussian multiplication: 5 Hz and 
exponential multiplication: −3 Hz), residual water suppression by 
high-pass filtering (width 30 Hz) and fast Fourier transformation. 
By using prior knowledge of the expected metabolites, SpectroView 
quantified the frequency domain data by phase correction and the 
fitting of peaks. The baseline was fitted by a polynomial function 
and subtracted from the whole spectrum. Based on the peak 
integrals of the main metabolites NAA (2.0 ppm), Cr (3.1 ppm), 
Cho (3.2 ppm), mI (3.6 ppm), and lipid (Lip0.9ppm and Lip1.3ppm, 0.9 
and 1.3 ppm), metabolite ratios were calculated (NAA/Cr, NAA/
Cho, Cho/Cr, and Lip/Cr). The acquired spectra without water 
suppression were used to calculate the peak integral of the unsup-
pressed water signal for each voxel. This spectral analysis covered 
metabolite ratios extracted separately in the center of PML lesions 
FigUre 1 | Exemplary course of progressive multifocal leukoencephalopathy (PML) in a single patient visualized by conventional magnetic resonance imaging 
(fluid-attenuated inversion recovery-sequence and Gadolinium-enhanced T1 sequence) and 1H-MRS during the pre-immune reconstitution inflammatory syndrome 
(IRIS) phase [(a) upper row], IRIS phase [(B) middle row], 5 months post-PML phase [(c) third row], and 11 months post-PML phase [(D) lower row].
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and in contralateral NAWM in each patient, and non-PML MS 
lesions whenever possible.
Metabolite ratios of peak integrals of single spectra are widely 
used to report results of brain spectroscopy, when no external 
reference for the determination of absolute metabolite concentra-
tions is available, and allow for the comparison of results between 
different studies. The Cr peak integral is commonly chosen as 
the denominator in these ratios because Cr, being related to 
the intracellular energy states, seems to remain relatively stable 
in many pathological situations and in different brain regions. 
Consequently, variations of the Cr-based metabolite ratios 
are interpreted as changes of the metabolite in the numerator. 
However, the assumption of constant Cr levels seems not to be 
valid in certain pathologies, such as acute ischemic stroke (31), 
various primary brain tumors (32), and notably in MS lesions 
(33, 34). Thus, aiming to investigate changes of the single 
metabolites in different phases of the PML disease, we calculated 
ratios of the peak integrals in PML lesions related to the cor-
responding peak integral of the contralateral voxel of NAWM: 
NAAPML/NAANAWM (NAAPML/NAWM), CrPML/CrNAWM (CrPML/NAWM), 
ChoPML/ChoNAWM (ChoPML/NAWM), LipPML/LipNAWM (LipPML/NAWM). 
We corrected these so-called “single metabolite ratios” for pos-
sible errors induced by imperfect contralateral positioning of the 
voxels by prior division of each metabolite’s peak integral by the 
corresponding peak integral of unsuppressed water. Bearing in 
mind that this procedure relies on the assumptions, that the water 
concentrations in PML lesion and NAWM are similar, and that 
the spectral patterns in NAWM are stable during the different 
PML phases, the results of these single metabolite ratios can only 
be interpreted as an estimation of the true courses of the single 
metabolite changes in PML lesions.
statistical analysis
SPSS 22 (IBM SPSS, Chicago, IL, USA) was used for all statis-
tical analyses. Due to the relatively small group sizes, we used 
non-parametric statistical tests. Group differences between the 
spectral results of PML lesions in the PML status groups, NAWM, 
and non-PML MS lesions were assessed by non-parametric 
Kruskal–Wallis tests. If these results were significant, SPSS 22 
calculated post hoc pairwise comparisons corrected for multiple 
comparisons based on Dunn–Bonferroni tests (35). In addition, 
the group results of the metabolite ratios were visualized by box-
plots (median, interquartile range, minimum, maximum).
Associations between MRS results in PML lesions and the time 
interval relative to IRIS in the entire patient group were assessed 
by Spearman correlation analyses. Correlations between disability 
parameters (KPS and EDSS) and metabolite ratios in PML lesions 
and single metabolite ratios (relating the peak integrals in PML 
lesion to contralateral NAWM) were also investigated by separate 
Spearman correlation analyses in the PML status subgroups.
resUlTs
Demographic Data
Table 1 summarizes demographic data and clinical status at the 
time of 1H-MRS examination and one year before the occurrence 
of PML of all patients. Mean age, disease duration, and the 
number of natalizumab infusions before PML were (mean ± SD) 
42 ± 10 years, 11.5 ± 5.5 years, 50 ± 19 infusions, respectively. 
It should be noted that if there were follow-up investigations 
available, one individual patient contributed 1H-MRS-results in 
different PML status groups.
PMl lesion characteristics
The individual PML lesion presentation in conventional MRI at 
the time of MRS compared to the situation at PML diagnosis and 
PML–IRIS was assessed. The details are provided in the Table S1 
in Supplementary Material in the additional online material. All 
patients with supratentorial PML had typical MRI features with 
progressive PML lesion evolution after onset, large lesions in 
FLAIR imaging with typically subcortical location extending into 
the gyrus and U-fiber involvement. Three patients had infratento-
rial PML with brainstem and cerebellar involvement. Contrast 
enhancement has been observed in all patients at PML–IRIS. 
The PML lesions were hypointense on unenhanced T1 weighted 
images in most of the cases except three patients in the pre-IRIS 
and early IRIS phase. The majority of patients who received 
MRS examination in the post-PML phases showed considerable 
brain atrophy at the PML lesion locations. To characterize the 
PML lesions, a semi-quantitative MRI sum score was derived 
which describes the extent of the lesions and the affected brain 
region on FLAIR weighted imaging (range 1–9: 1 = focal lesions 
affecting one gyrus, 9 =  bi-hemispheric lesions covering both 
hemispheres).
1h-Mrs Findings
Figure 1 illustrates exemplarily the longitudinal brain metabolite 
changes during the course of the PML-disease in a PML lesion 
of a single patient (left column). The first MRS examination was 
acquired 3  weeks after PML diagnosis and immunoadsorption 
to remove natalizumab. FLAIR-weighted MR images depict the 
PML lesions and the localization of the spectra (middle column). 
The extension of the FLAIR lesions increased from the pre-IRIS 
phase until 5 months after PML–IRIS and was found decreased 
at 11 months after IRIS. Contrast-enhanced T1 weighted images 
(right column) showed subtle signs of contrast accumulation 
concordant with early inflammatory PML in the pre-IRIS phase, 
marked rim and punctuate enhancement in the IRIS phase, 
and increasing T1 hypointensity at the PML lesion location. In 
pre-IRIS PML lesion spectrum (Figure  1A) compared to the 
pooled NAWM results (Table 2), we saw reduced levels (>1 SD) 
of NAA/Cr and NAA/Cho (lesion vs. NAWM: NAA/Cr 1.17 vs. 
1.50 ± 0.28; NAA/Cho 1.09 vs. 1.98 ± 0.57) and an increase in 
Lip/Cre which exceeded 2 SDs (lesion vs. NAWM: Lip/Cr 0.96 
vs. 0.50 ± 0.21) in a location at which a large PML lesion arose 
only later on, in the IRIS and post-IRIS phase. In the IRIS phase 
(Figure 1B), marked increases of Cho/Cr and lipid were apparent 
as compared to the pre-IRIS phase at the same location. Cho/
Cr and Lip/Cr decreased in the post-PML phases [(Figure 1C), 
5 months after IRIS] and ceased even more 11 months after IRIS 
(D), although they were still elevated compared to the pre-IRIS 
spectrum. In the spectra acquired in the IRIS and early post-
IRIS phase (Figures  1B,C), the rising of the lipid signals were 
TaBle 1 | Demographic and clinical characteristics of participants.
Pat. no. age range at 
Mrs (years)
Duration between 
Ms diagnosis and 
PMl (years)
no. of naBa 
infusions
PMl group Duration since 
iris (days)b
eDss at 
Mrs
eDss at 1 year 
before PMl
KPs at 
Mrs
KPs at 1 year 
before PMl
1 60–65 19 96 Pre-IRIS −31 4.5 2 80 90
1 IRIS 0 6.5 2 40 90
1 E-post-PML 155 5.5 2 50 90
1 E-post-PML 340 5.5 2 50 90
2 40–45 23 55 E-post-PML 341 6.5 2 50 70
3 20–25 4 22 E-post-PML 372 2.5 2 90 90
4 26–30 6 49 E-post-PML 550 3.5 2 70 100
5 36–40 8 48 E-post-PML 589 1.5 1.5 100 100
6 40–45 6 48 L-post-PML 713 4 2 70 80
7 40–45 9 51 L-post-PML 806 5.5 3.5 60 80
7 L-post-PML 1,426 5 3.5 70 80
8 36–40 16 49 L-post-PML 837 4 2.5 67 90
9 30–35 11 62 L-post-PML 899 7.5 1 50 100
10 46–50 11 37 L-post-PML 1,178 4 2.5 80 90
11 50–55 17 40 L-post-PML 1,178 5 2 80 100
12 36–40 7 26 L-post-PML 1,395 6.5 3.5 60 70
13 30–35 9 30 L-post-PML 1,581 7 1.5 60 90
14 40–45 4 27 L-post-PML 1,736 5 2 40 100
15 36–40 12 34 L-post-PML 2,077 6.5 2 50 90
16 50–55 13 70 Pre-IRIS −38 7 3.5 40 90
16 13 Pre-IRIS −14 7.5 3.5 30 90
17 60–65 21 41 Pre-IRIS −10 8 4 40 60
18 46–50 10 106 Pre-IRIS −40 3.5 2.5 70 90
18 10 IRIS 0 4 2.5 60 90
19 40–45 9 82 Pre-IRIS −30 3.5 2.5 80 90
19 9 IRIS 0 6.5 2.5 40 90
19 9 E-post-PML 120 5.5 2.5 60 90
19 9 E-post-PML 247 5 2.5 70 90
20 56–60 16 60 IRIS 0 4 4 60 90
aNAB = Natalizumab.
bNegative values for time before IRIS.
MRS, MR spectroscopy; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy; E-post-PML, early post PML; L-post-PML, late post-PML; EDSS, expanded 
disability severity scale; KPS, Karnofsky performance scale.
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dominated by the increase of the peak at 1.3  ppm (Lip1.3ppm) 
originating by protons in CH2 groups of fatty acids. Furthermore 
in this patient, a superimposition of lactate signal was visible in 
(Figures 1B,C) at this peak position.
Table 2 summarizes the 1H-MRS-results within the different 
patient groups regarding the integrals of metabolite peaks derived 
in the center of PML lesions at different PML phases and in 
NAWM and some (non-PML)-MS lesions. We compared to the 
metabolite ratios of the main metabolites (NAA, Cr, Cho, and 
Lipid) within voxels of PML lesions, NAWM, and non-PML-MS 
lesions. In addition, we regarded single metabolite ratios by 
calculating the ratios of the signal areas in PML lesion compared 
to NAWM voxels, in order to estimate the change of the single 
metabolites during different phases of PML. Figures  2 and 3 
(boxplots) further illustrate these interrelations.
The Kruskal–Wallis tests showed highly significant differences 
between the subgroups for NAA/Cr, NAA/Cho, Cho/Cr, and Lip/
Cr. Post hoc pairwise comparisons showed significant elevations 
of Lip/Cr at the PML lesion locations in the pre-IRIS, IRIS, and 
the early post-PML phases relative to NAWM and relative to PML 
lesions in the late post-PML setting. These Lip/Cr increases were 
highest in the IRIS phase. In line, NAA/Cho was reduced in PML 
lesions in the pre-IRIS, IRIS (most reduced), and early post-PML 
phases compared to NAWM.
Cho/Cr was considerably increased relative to NAWM 
exclusively in the IRIS phase. By contrast, NAA/Cr was con-
stantly reduced in all PML phases compared to NAWM and MS 
lesions, reaching statistically significance compared to NAWM 
in pre-IRIS and early post-PML lesions. Thus, Lip/Cr and Cho/
Cr seemed to be the most promising dynamic metabolite ratios 
that were related to the onset of the IRIS phase in PML. Figure 2 
further illustrates these interrelations.
The single metabolite ratios of PML lesions relative to the con-
tralateral NAWM voxel (Table 2; Figure 3) showed reduced levels 
(<1.0) of NAAPML/NAWM in all PML phases, which were lowest in 
the IRIS group, while the differences between the PML groups 
were not significant (Figure 3C).
Creatine (Figure  3D): compared to the pre-IRIS phase, in 
which Creatine PML/NAWM was elevated (>1.0), we observed a 
significant reduction of the Cr PML/NAWM level in the IRIS group, 
and increasing Cr PML/NAWM levels in the post-PML phases reaching 
close-to-normal levels in the late post-PML group.
Choline (Figure  3B): we observed markedly elevated Cho 
PML/NAWM levels in pre-IRIS and IRIS patients without significant 
TaBle 2 | Results of 1H MRS: metabolite ratios in PML lesions subdivided into different PML phases, compared to NAWM and non-PML MS lesions (NAA/Cr,  
NAA/Cho, Cho/Cr, Lip/Cr) and single metabolite ratios of the results in a PML voxel divided by the result in the corresponding voxel in contralateral NAWM (NAAPML/NAWM, 
CrPML/NAWM, ChoPML/NAWM, Lipsum PML/NAWM, Lip1.3ppm PML/NAWM, Lip0.9ppm PML/NAWM).
Median [range]
PMl lesions naWM Ms lesions pa
Pre-iris iris early post PMl late post PMl
N 6 4 8 11 29 6
NAA/Cr 0.96 [0.81–1.17]  
p = 0.003b (NAWM) 
p = 0.018b (MS)
1.2 [0.8–1.3] 1.0 [0.5–1.7]  
p = 0.012b (NAWM)
1.2 [0.9–1.4] 1.5 [0.8–2.1] 1.5 [1.2–2.1] <0.001
NAA/Cho 0.99 [0.79–1.14] 0.6 [0.4–0.7]  
p = 0.001b (NAWM)
1.1 [0.5–2.5]  
p = 0.018b (NAWM)
1.5 [0.9–2.0] 1.8 [1.2–3.2] 1.7 [1.0–2.5] <0.001
p = 0.004b (NAWM)
Cho/Cr 1.05 [0.78–1.14] 2.1 [1.2–2.9]  
p = 0.003b (NAWM)
0.9 [0.7–1.3] 0.9 [0.7–1.2] 0.8 [0.5–1.3] 0.9 [0.7–1.3] 0.002
Lip/Cr 1.5 [0.5–3.4]  
p = 0.014b (NAWM)  
p = 0.025b (L-post-PML)
2.6 [1.2–4.2]  
p = 0.004b (NAWM)  
p = 0.006b (L-post PML)
1.1 [0.6–2.1]  
p = 0.007b (NAWM) 
p = 0.017b (L-post PML)
0.4 [0.1–1.0] 0.5 [0.2–1.1] 0.7 [0.5–1.7] <0.001
NAAPML/NAWM 0.63 [0.54–0.99] 0.5 [0.3–0.6] 0.5 [0.3–0.9] 0.7 [0.5–1.1] 0.094
CrPML/NAWM 1.19 [0.70–1.33]  
p = 0.111b(E-post-PML)
0.6 [0.4–1.0]  
p = 0.072b (pre-IRIS)
0.8 [0.3–1.0] 0.9 [0.6–1.5] 0.037
ChoPML/NAWM 1.35 [0.96–1.61]  
p = 0.008b (E-post-PML)
1.2 [1.1–1.7]  
p = 0.055b (E-post-PML)
0.8 [0.6–1.2] 1.1 [0.5–1.9] 0.006
Lipsum PML/NAWM 2.64 [1.47–3.78] 3.1 [2.5–3.3]  
p = 0.039b (L-post-PML)
2.0 [1.1–3.2] 1.5 [0.5–3.4] 0.028
Lip1.3ppm PML/NAWM 3.40 [2.49–5.25]  
p = 0.109b (L-post-PML)
6.1 [2.7–10.2]  
p = 0.025b (L-post-PML)
3.0 [1.3–7.2] 1.5 [0.7–3.5] 0.015
Lip0.9 ppm PML/NAWM 2.08 [1.30–2.68] 1.5 [1.1–3.8] 1.6 [0.2–3.2] 1.1 [0.2–4.5] 0.609
aSignificance p of differences between groups by Kruskal-Wallis tests.
bSignificant post hoc pairwise comparisons, corrected for multiple comparisons by Dunn-Bonferroni correction.
NAWM, normal appearing white matter; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy; IRIS, immune reconstitution inflammatory syndrome; NAA, 
N-acetyl aspartate; Cr, Creatine; Cho, Choline; Lip, Lipid; L-post-PML, late post-PML.
7
Schneider et al. 1H-MRS in Natalizumab-Associated PML
Frontiers in Neurology | www.frontiersin.org September 2017 | Volume 8 | Article 454
differences between these groups. By contrast, in the early post-
PML group the Cho PML/NAWM ratio was significantly lower (<1.0) 
than in the pre-IRIS and IRIS groups.
Lipid (Figure 3A): the single metabolite ratios of the summed 
lipid signal in PML compared to NAWM were high in pre-IRIS 
and highest (> = 3) in the IRIS group. Lipsum PML/NAWM was lower, 
but still considerably elevated compared to NAWM in early post-
PML. Also in late post-PML patients, the Lipsum PML/NAWM ratio was 
higher than normal; the differences in comparison to the IRIS 
patients were highly significant in this group.
In Table  2, we additionally analyzed the lipid contributions 
of the peaks at 0.9 ppm (CH3 groups) and 1.3 ppm (CH2-groups) 
separately. We found that the increase of the summed lipid signal 
was dominated by Lip at 1.3 ppm. The levels in pre-IRIS and IRIS 
were markedly elevated in Lip1.3ppm PML/NAWM (≥6; highly significant 
in comparison to the late post-PML setting), reaching up to 4-fold 
values as compared to Lip0.9ppm PML/NAWM in the IRIS phase.
correlation analysis of 1h-Mrs Metabolite 
ratios in PMl lesions and Time 
Difference to iris
Spearman correlation analysis demonstrated a significant steady 
increase of Lip/Cr depending on the time period before the occur-
rence of IRIS (ρ = 0.619, p = 0.028). Furthermore, in the post-IRIS 
phase, Lip/Cr levels were significantly negative correlated with 
the time difference after IRIS (ρ = −0.518, p = 0.014), indicating 
a slow decline to normal levels. In contrast to Lip/Cr, the levels 
of Cho/Cr were elevated uniquely at the time of IRIS and were 
normal in the pre- and post-IRIS phases. Figure  4 illustrates 
these correlations; patients who received follow-up examinations 
are marked by five different colors. These associations were also 
reflected by the individual longitudinal courses of Lip/Cr and 
Cho/Cr in three of the four patients who had follow-up examina-
tions in the pre-IRIS and IRIS phase. In one patient who showed 
no marked increases of Lip/Cr or Cho/Cr in the PML lesion at 
IRIS (no. 19, orange symbols in Figure 4), MRS was acquired at 
the beginning of PML–IRIS, which was defined by subtle signs 
of Gadolinium enhancement in the PML lesion. The full clinical 
IRIS manifestation with considerable increase of gadolinium 
enhancement in MRI was observed 2 weeks after the MRS. For 
this reason, Lip/Cr and especially Cho/Cr increases might have 
been missed by the MRS assigned to the IRIS phase in this patient.
Furthermore, when regarding the single metabolite ratios of PML 
lesions compared to contralateral NAWM we observed significant 
negative correlations of NAA PML/NAWM and Cr PML/NAWM in the pre-IRIS 
and IRIS phase (ρ = −0.825, p = 0.002, and ρ = −0.732, p = 0.008) 
with time difference before IRIS, indicating a steady decrease of 
the NAA PML/NAWM and Cr PML/NAWM in that phase of the disease. The 
decrease of the NAA PML/NAWM and Cr PML/NAWM levels during the time 
between the PML diagnosis and occurrence of PML–IRIS was also 
found in the individual follow-up examinations. In the post-IRIS 
FigUre 2 | Qualitative group comparisons between different progressive multifocal leukoencephalopathy (PML) phases shown as boxplots for main metabolite 
ratios Lipsum/Cr (a): upper row left panel, Cho/Cr (B): upper row right panel, NAA/Cho (c): lower row left panel, NAA/Cr (D): lower row right panel. Boxes, 
interquartile range; line, median; and error bars, minimum–maximum; pre-immune reconstitution inflammatory syndrome (IRIS), IRIS, early post-PML, and late 
post-PML represent spectral results in PML lesions; normal appearing white matter (NAWM) and multiple sclerosis (MS) show pooled spectral results in NAWM and 
non-PML MS lesions. Significant group differences (pairwise testing after significant Kruskall–Wallis tests; corrected for multiple comparisons by Dunnett–Bonferroni 
tests) are marked by ** if p < 0.010, * if p < 0.050, (*) for trends: 0.050 ≤ p < 0.100.
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phase, there were no significant correlations of the single metabolite 
ratios with the time after PML–IRIS. Details of this analysis are 
illustrated in the Figures S1 and S2 in Supplementary Material.
correlation analysis of 1h-Mrs Metabolite 
ratios and Disability status
All PML patients clinically worsened indicated by a marked EDSS 
increase and a KPS decrease within 1-year interval before PML 
and during pre-IRIS/IRIS. In the post-PML period, the patients 
recovered (24) as compared to IRIS.
To investigate associations between the 1H-metabolite ratios 
and clinical disability, the differences of KPS and EDSS between 
the time point of 1H-MRS and 1 year before PML were analyzed. 
Pre-IRIS and IRIS phases (raising Lip/Cr and Cho/Cr and 
decreasing NAA/Cho levels) and the post-PML phases (decreas-
ing Lip/Cr and Cho/Cr, recovery of NAA/Cho) were analyzed 
separately.
In the post-PML group (N  =  19), Spearman correlation 
analyses showed a significant positive correlation between NAA/
Cho in PML lesions and the KPS change (ρ = 0.481, p = 0.018), 
significant negative correlations between Cho/Cr and the KPS 
change (ρ = −0.505, p =  0.014) and Lipsum PML/NAWM and KPS 
change (ρ = −0.488, p = 0.020). In the pre IRIS and IRIS patients 
(N = 10), the increase of the lipid peak at 1.3 ppm in PML lesions 
relative to NAWM, Lip1.3ppm PML/NAWM, was significantly negative 
correlated with the KPS change (ρ = −0.669, p = 0.017). Figure 5 
illustrates these associations. No other significant correlations of 
the KPS or the EDSS were observed in any subgroup.
FigUre 3 | Group comparisons between different PML phases shown as boxplots for single metabolite ratios comparing PML lesions with contralateral NAWM for 
NAA PML/NAWM, and Lipsum PML/NAWM (a): upper row left panel, Cho PML/NAWM (B): upper row right panel, NAA PML/NAWM (c): lower row left panel, Cr PML/NAWM (D): lower row 
right panel. Boxes: interquartile range, line: median, error bars: minimum-maximum; Significant group differences (pairwise testing after significant Kruskall Wallis 
tests; corrected for multiple comparisons by Dunnett–Bonferroni tests) are marked by ** if p < 0.010, * if p < 0.050, (*) for trends: 0.050 ≤ p < 0.100.
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DiscUssiOn
In this explorative 1H-MRS study, characteristic metabolic 
changes in brain lesions of 20 MS patients were examined at 
different stages during the course of natalizumab-associated 
PML. The differences of the metabolic patterns between different 
PML stages in the cross-sectional investigations were supported 
by concordant results of the longitudinal course in follow-up 
examinations of five PML patients.
Metabolic changes during  
PMl–iris Phase
Lipid and Choline resonance normalized to Creatine were the 
most promising metabolic markers for detecting the onset 
of the IRIS phase in the course of the PML disease: while Lip/
Cr increased before the occurrence of IRIS with a maximum 
manifestation during the PML–IRIS phase, marked rises of Cho/
Cr were found exclusively during the IRIS phase. Significant 
negative correlations between Lip/Cr and the number of days 
before IRIS and between Lip/Cr and the time after IRIS addition-
ally confirmed the clinical relevance of the Lip/Cr ratio. Several 
days before PML–IRIS, the Lip/Cr ratio already seems to increase 
continuously, which could be helpful in detecting the onset of 
PML IRIS with the consequence of the initiation of a standardized 
recommended therapy regime (9).
The additional estimation of the changes of the individual 
metabolite signals throughout the different PML phases by 
assessment of the ratios in the PML lesions compared to the 
contralateral NAWM voxel indicated a decrease of Cr from 
slightly above-normal levels in the pre-IRIS to markedly sub-
normal levels in the IRIS phase. This drop of the Cr level prob-
ably contributed to the observed changes of Lip/Cr and Cho/
FigUre 4 | Dependence of Lip/Cr and Cho/Cr on the time difference between the MRS examination and the onset of IRIS. Gray symbols: all patients who had a single MRS 
examination; red symbols, patient no. 1; green symbols, patient no. 16; blue symbols, patient no. 18; orange symbols, patient no. 19 (here: IRIS = early IRIS with beginning of 
contrast enhancement), light blue symbols, patient 7. Dotted lines: linear regression of Lip/Cr and time difference before (R2 = 0.415) and after IRIS (R2 = 0.256).
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Cr. Lipsum PML/NAWM showed steadily increasing levels with time to 
IRIS onset, which was accentuated by Lip/Cr. ChoPML/NAWM was 
similarly increased in pre-IRIS and in IRIS, so the Cho/Cr ratio 
may emphasizes the change due to reduced CrPML/NAWM especially 
during PML–IRIS. For the first time, these effects were demon-
strated cross-sectionally, but also in follow-up examinations.
The metabolic changes relating to lipid and choline levels were 
probably evoked by the progressive inflammation-situation that 
FigUre 5 | Associations between metabolite results and progressive multifocal leukoencephalopathy (PML)-related disability [change of Karnofsky Performance 
Scale (KPS) between time of MRS and 1 year before PML] in the pre-immune reconstitution inflammatory syndrome (IRIS) and IRIS phase, and in the post-PML 
phase; only significant correlations are depicted. Dotted lines and R2: linear regression line and coefficients of determination.
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has already been seen in HIV-related PML (18). In vitro studies 
demonstrated an association between MRS-visible lipids and 
the presence of activated immune cells, especially T  cells (36), 
proposing the role of lipids as a marker for activated lympho-
cytes (37). Furthermore, the release of mobile lipids consisting of 
triglycerides and cholesterol esters was interpreted as an indica-
tor for increased membrane fluidity, which may facilitate the 
migration of T cells (37). To gain further information about the 
metabolic pattern of lipids, we regarded the different resonances 
at 0.9 ppm (CH3 methyl groups in fatty acids) and 1.3 ppm (CH2 
methylene groups). The total lipid peak (Lip sumPML/NAWM), which 
was increased in pre-IRIS and IRIS, was dominated by the marked 
increase of the peak at 1.3 ppm. Due to the chemical structure of 
fatty acids the proportion of CH2 to CH3 groups should lead up 
to eight-fold higher signals at 1.3 ppm than at 0.9 ppm, if lipids 
were the only source of the signal in this frequency range (38). 
The relatively high ratios of the signals at 1.3 ppm compared to 
0.9 ppm (up to fourfold) indicate a considerable fraction of free 
lipid production as a source of this signal increase at IRIS. This 
could be partly influenced by overlaid lactate signal, which may 
be attributed to anaerobic metabolism and activated glycolysis in 
macrophages (39). Considering the fact that the 0.9 ppm reso-
nance was also significantly elevated compared to the post-PML 
setting, the presence of mobile lipids and pathologically altered 
macromolecules should be taken into consideration as sources of 
these signal increases (40). In a previous study, the elevation of the 
resonances at 0.9 and 1.3 ppm was significantly higher in acute 
MS lesions than in chronic MS lesions. These signals have been 
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interpreted as free lipids, and increased macromolecules contrib-
uting to both resonances, which were conceivably interpreted as 
biochemical markers of myelin fragments (38). We hypothesize 
that this interpretation might be transferable to acute PML (pre-
IRIS and IRIS) in order to distinguish it from the post PML setting, 
which would provide useful additional diagnostic information 
in this context. In summary, it can be stated that elevated lipid 
resonances could be influenced by several conditions due to acute 
inflammation, like infiltration of activated T cells into the brain 
tissue, and varying proportions caused by overlaid lactate as well 
as demyelination inducing the detectability of macromolecular 
fragments.
contrast enhancement and Metabolic 
changes during PMl–iris Phase
The specificity of MRI contrast enhancement for the onset of IRIS 
is limited, especially with respect to milder inflammatory PML 
(23) and the absence of enhancement should not preclude clinical 
consideration of IRIS (10, 15, 16). Therefore, the observed increase 
of the Lip/Cr ratio in PML lesions before IRIS by 1H-MRS can 
provide useful additional information and an early marker for 
the detection of PML–IRIS. Especially in case of asymptomatic 
PML patients, early diagnosis before onset of symptoms is very 
important concerning survival and clinical outcome (4).
In HIV-associated PML–IRIS, the increase in Cho/Cr ratio, 
which is interpreted as an indicator for demyelination and mem-
brane turnover, was associated with MR evidence of contrast 
enhancement, whereas increased Lip/Cr ratios were independ-
ent of contrast enhancement (18). The present results confirmed 
these findings in natalizumab-related PML in MS, in which the 
flashback of the immune system and, thus, IRIS is usually more 
pronounced than in HIV–PML. An elevated Cho/Cr ratio was 
merely seen in the IRIS phase during contrast enhancement of 
the PML-lesion. Increased Cho/Cr ratios were found in other 
demyelinating and inflammatory conditions, in the context of 
increased membrane turnover, emphasizing the role of Choline 
as a component of the cell membrane (41). Therefore, evaluation 
of the combined pattern of the Lip/Cr and Cho/Cr ratios may be 
helpful to characterize the onset and course of the IRIS phase.
Metabolic changes regarding 
neuroaxonal integrity during the  
course of PMl
The NAA/Cr ratio, which is a characteristic metabolic marker 
for neuroaxonal integrity (42), was reduced in PML lesions 
compared to NAWM in the pre-IRIS and early post-PML group, 
but was not significantly different when comparing the different 
PML phases. We interpret this finding by early and long-lasting 
axonal loss in PML lesions compared to NAWM. In the IRIS 
group, we observed a non-significant increase of NAA/Cr. By 
contrast, in HIV-associated PML-lesions, the NAA/Cr ratio was 
described to be decreased in PML–IRIS but was classified as less 
specific based on most diverse inflammatory processes resulting 
in neuronal or axonal damage (18). When regarding the single 
metabolite ratios, we found a reduction of both NAAPML/NAWM 
and CrPML/NAWM during the IRIS phase. The significant negative 
correlations relating the decrease of NAA PML/NAWM and Cr PML/
NAWM in the pre-IRIS and IRIS phase with time between the PML 
diagnosis and occurrence of PML–IRIS indicated a continuous 
reduction of NAA and Cr before IRIS, which was confirmed 
by the follow-up investigations. These simultaneous decreases 
probably explain the subsequent, relative constant levels of 
NAA/Cr.
However, in PML–IRIS, the interpretation of a reduction of 
Cr is speculatively regarding the drawback of the small patient 
number in this group. Reduced Cr levels compared to NAWM 
have been reported in chronic MS lesions (34). But still, increases 
of Cr during inflammatory CNS demyelination have been 
described in RR-MS (43, 44). These were interpreted as higher 
cell densities per spectroscopic VOI in glial structures, provided 
that neuroaxonal structures, which harbor Cr for their cellular 
homeostasis and energy supply, are still intact (45). By implica-
tion, in PML–IRIS the reduction of Cr could be interpreted as 
lower cell density and loss of intact neuroaxonal structures due 
to fatal cell break-down after a regulatory increase of CrPML/NAWM 
in pre-IRIS caused by inflammation in the presence of still-intact 
neuroaxonal structures. The return of CrPML/NAWM to normal 
values in chronic states may reflect regeneration processes driven 
by oligodendrocyte migration and astrocytic or oligodendrocytic 
remyelinating processes (44).
Considering the metabolic changes of NAA/Cho during the 
course of the disease, we showed dynamic changes with a reduced 
NAA/Cho ratio in pre-IRIS and a maximal decrease in PML–
IRIS followed by restitution in the post-PML setting to level of 
NAWM. According to literature, the increase of Cho outweighs 
the decrease of NAA in new PML lesions compared to older 
lesions. We suggest that demyelinating processes may dominate 
neuronal loss in active PML lesions, while neuroaxonal loss is 
probably the main effect in older PML lesions (19). Regarding 
the single metabolite ratios of ChoPML/NAWM, this interpretation 
was supported since Choline was elevated in pre-IRIS and IRIS 
compared to early-post-PML, reflecting dynamic changes in an 
ongoing disease activity. Thus, NAA/Cho may reflect dynamic 
metabolic changes during the course of PML disease but is less 
suitable for the detection of the onset of IRIS as it combines two 
different pathological processes leading to opposite effects on the 
metabolite ratio.
association between Metabolite  
Patterns and clinical Parameters
As far as we know, the association between 1H-MRS-acquired 
metabolite patterns and clinical parameters in MS patients at 
post-IRIS stages of natalizumab-associated PML have only been 
analyzed the authors’ own previous work (22). In this study, the 
therein reported associations between Cho/Cr and the PML-
related disability burden were confirmed in a larger patient group. 
Correlations between Cho/Cr, NAA/Cho and LipsumPML/NAWM and 
KPS change in post-PML patients, associating the worse clinical 
outcome of PML survivors with persistently high Cho/Cr, low 
NAA/Cho, and high lipid levels were demonstrated. We suppose 
that Cho/Cr and LipsumPML/NAWM, reflecting increased membrane 
turnover in demyelinating and inflammatory conditions, may 
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correspond to more severe clinical affection because of ongoing 
inflammatory activity in PML lesions.
Moreover, NAA/Cho, representing a dynamic metabolic 
marker, seems to have clinical relevance in the post-PML setting. 
Persistent clinical disability may be a result of ongoing neuroax-
onal degeneration and demyelination, reflected by low NAA/Cho 
levels.
In the pre-IRIS and IRIS groups, the additive analysis of the 
lipid resonance at 1.3  ppm, which was significantly increased 
in PML–IRIS showed a negative correlation with KPS change 
reflecting that higher lipid levels at 1.3  ppm were associated 
with a worse clinical status in acute PML. The correlation of 
the summed LipPML/NAWM in the summarized post-PML group 
with KPS-change could reflect the persistent presence of lipids 
in later PML stages as a possible marker of reduced clinical 
convalescence.
limitations
A few limitations of this survey need to be mentioned. The 
main limitation is the small number of included patients for 
follow-up MRS in the pre-IRIS and IRIS group characterizing 
the explorative manner of this study. Furthermore, since most 
of the included patients received only one MRS examination 
the probable temporal course of the metabolic changes related 
to PML was mostly deduced from these cross-sectional results, 
although the conclusions were strongly supported by evidence 
from concording follow-up examinations of five patients. As 
such, the herein presented preliminary results may differ from 
longitudinal examination of individual patients and should, 
therefore, be interpreted with caution.
Generally, it has to be stated that acquiring a large number of 
homogeneous longitudinal MR spectroscopic and imaging data 
on PML patients is a difficult task for several reasons: first, MRS 
is time-consuming (acquisition about 10  min.) and demands 
experienced users. Longitudinal MRS examinations have to 
be performed at a single scanner using a homogeneous scan 
protocol to ensure reproducibility of these examinations. Thus, 
patients have to be enrolled for suspected or early PML before 
the onset of IRIS and followed-up over a longer period in a single 
center. Since PML–IRIS is often accompanied by massive clinical 
worsening, requiring intensive care, these circumstances often 
prohibit prolonged MR scanning including MRS.
Another limitation is the lack of absolute metabolite quanti-
fication in this study. Apart from the presentation of metabolite 
ratios, we could only provide an estimation of the changes of 
the single metabolites by comparing the results in PML voxels 
with contralateral NAWM. These single metabolite ratios can 
be biased by occult disease related changes within the NAWM 
and by imperfect contralateral voxel positioning. Future studies 
should include absolute metabolite quantification techniques 
providing independent external concentration references. 
Furthermore, in the context of PML–IRIS, dedicated procedures 
for quantification of lipids and distinction from macromolecules 
and lactate, such as the metabolite nulling technique (38), should 
be used.
Natalizumab-associated PML is a rare complication of 
MS treatment. Thus, it is not probable that a single academic 
MS center will treat and follow-up many patients living in the 
nearby region for suspected PML in a reasonable time period. 
Instead, most patients will be referred to the center in the acute 
onset-phase of PML or for a second opinion and will be treated 
longitudinally in their home area. Others will be referred to the 
center in the post-PML setting for decision about reinitiation of 
an immunomodulatory MS treatment.
In future studies, common efforts of several MS centers using 
identical scanning protocols for imaging and MR spectroscopy 
would be desirable in order to gain longitudinal information 
about the temporal dynamics of brain metabolic MRS changes 
during the course of PML on a large number of patients.
In summary, our exploratory study provided indications that 
1H-MRS can be a helpful tool to detect characteristic dynamic 
changes with clinical relevance during the course of natalizumab-
associated PML in MS patients. The onset of PML–IRIS, in 
particular, was associated with rising Lip/Cr and Lipid resonance 
at 1.3 ppm and elevated Cho/Cr levels.
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